Previous 10 | Next 10 |
Amarin (NASDAQ:AMRN): Q3 Non-GAAP EPS of -$0.03 beats by $0.01; GAAP EPS of -$0.03 in-line. Revenue of $142.04M (-9.2% Y/Y) misses by $19.25M. Press Release As of September 30, 2021, Amarin reported aggregate cash and investments of $517.9M, consisting of cash and cash equivalents of $22...
Launched VAZKEPA in Germany with Multiple European Country Launches Expected in 2022 Introduced New Go-to-Market Strategy in U.S. to Enhance Awareness and Drive Demand for VASCEPA® Plans for Regulatory Filings and Approvals of VASCEPA in Several Additional Countries...
Amarin (NASDAQ:AMRN) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$0.04 (-500.0% Y/Y) and the consensus Revenue Estimate is $161.29M (+3.1% Y/Y). Amarin reported second-quarter results that beat Wall...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin’s senior management team to discuss the Company's third quarter 2021 financial results on ...
Growth stocks have seen their shares fall quite a bit recently due to lofty valuations and the rise in treasury yields. That’s why investors should consider adding value stocks to their portfolio. But instead of relying on traditional valuation measures, investors should consider stock...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many investors focus on value measurements, such as price-to-earnings or price-to-sales ratios. But to find underpriced top stocks, an even better method is to look at their upside potential based on analyst price targets....
Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...
Amarin Corporation plc (AMRN) Cantor Fitzgerald Global Healthcare 2021 Conference Transcript September 28, 2021, 2:40 PM ET Executives Karim Mikhail - Chief Executive Officer Analysts Louise Chen - Cantor Fitzgerald Presentation Louise Chen Hi. Good afternoon. I’m Louise Chen, the Larg...
Amarin's gross margin has been growing from year to year and by the end of Q2 2021 was around 79.2%, which is significantly higher than the average for the healthcare. Vascepa sales increased 15% in Q2 2021 compared to Q2 2020. In the next 18 months, the company should begin comme...
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA ® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...